Evidence map›Paper›PMID 32947953›Full record

ArticleCancers2020

Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer.

Bruna Cerbelli, Simone Scagnoli, Silvia Mezi, Alessandro De Luca, Simona Pisegna, Maria Ida Amabile, Michela Roberto, Lucio Fortunato, Leopoldo Costarelli, Angelina Pernazza and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Bruna CerbelliDepartment of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, 00161 Rome, Italy.
Simone ScagnoliDepartment of Medical Surgical Sciences and Translational Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0003-4943-5622
Silvia MeziDepartment of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0003-4746-2678
Alessandro De LucaDepartment of Surgical Sciences, Sapienza University of Rome, 00161 Rome, Italy.
Simona PisegnaDepartment of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, 00161 Rome, Italy.
Maria Ida AmabileDepartment of Surgical Sciences, Sapienza University of Rome, 00161 Rome, Italy.
Michela RobertoDepartment of Clinical and Molecular Medicine, Sapienza University of Rome, 00187 Rome, Italy.ORCID 0000-0001-5339-8348
Lucio FortunatoAzienda Ospedaliera San Giovanni-Addolorata, 00184 Rome, Italy.
Leopoldo CostarelliAzienda Ospedaliera San Giovanni-Addolorata, 00184 Rome, Italy.ORCID 0000-0002-9545-8123
Angelina PernazzaDepartment of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-8608-2734
Lidia StrigariMedical Physics Unit, "S. Orsola-Malpighi" Hospital, 40138 Bologna, Italy.
Carlo Della RoccaDepartment of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 00161 Rome, Italy.
Paolo MarchettiDepartment of Clinical and Molecular Medicine, Sapienza University of Rome, 00187 Rome, Italy.
Giulia d'AmatiDepartment of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-6959-691X
Andrea BotticelliDepartment of Clinical and Molecular Medicine, Sapienza University of Rome, 00187 Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) can predict better survival outcomes in patients with early triple negative breast cancer (TNBC). Tumor infiltrating lymphocytes (TILs), Programmed Death-Ligand 1 (PD-L1), and Cluster of Differentiation 73 (CD73) are immune-related biomarkers that can be evaluated in the tumor microenvironment. We investigated if the contemporary expression of these biomarkers combined in a tissue immune profile (TIP) can predict pCR better than single biomarkers in TNBC. Tumor infiltrating lymphocytes (TILs), CD73 expression by cancer cells (CC), and PD-L1 expression by immune cells (IC) were evaluated on pre-NACT biopsies. We defined TIP positive (TIP+) as the simultaneous presence of TILS ≥ 50%, PD-L1 ≥ 1%, and CD73 ≤ 40%. To consider the effects of all significant variables on the pCR, multivariate analysis was performed. Akaike information criterion (AIC) and Bayesian information criterion (BIC) were used for model selection. We retrospectively analyzed 60 biopsies from patients with TNBC who received standard NACT. Pathological complete response was achieved in 23 patients (38.0%). Twelve (20.0%) cases resulted to be TIP+. The pCR rate was significantly different between TIP+ (91.7%) and TIP- (25.0%) (

Indexed as

CD73neoadjuvant chemotherapypathological complete responsePDL1TILstissue immune profiletriple-negative breast cancer

Identifiers

PMID32947953
PMCPMC7565153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.